BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

NCT07625644 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

550

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer Extensive Stage
Small-cell Lung Cancer
Small Cell Carcinoma
Sclc
SCLC,Extensive Stage
Lung Cancer
Lung Cancer Metastatic
Lung Cancer Stage IV

Interventions

DRUG: BL-M14D1 and Atezolizumab
DRUG: Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin

Sponsor

SystImmune Inc.